Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

Dapagliflozin, a sodium‐glucose cotransporter 2 (SGLT‐2) inhibitor, has been shown to lower glycated hemoglobin (HbA1c), weight, blood pressure and serum uric acid in clinical trials. Plasma lipids were also evaluated as exploratory variables. The goal of this study was to estimate the long‐term cardiovascular (CV) and microvascular outcomes of dapagliflozin added to the standard of care (SOC) versus SOC using simulation methodology.

[1]  J. Rosenstock,et al.  Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes , 2012, Diabetes Care.

[2]  E. Ford.  Trends in the Risk for Coronary Heart Disease Among Adults With Diagnosed Diabetes in the U.S. , 2011, Diabetes Care.

[4]  Xiao-Hua Zhou,et al.  Allopurinol and mortality in hyperuricaemic patients. , 2009, Rheumatology.

[5]  C. Bailey,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.

[6]  I. Holme,et al.  Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417 734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS) , 2009, Journal of internal medicine.

[7]  N. Sattar,et al.  Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials , 2009, The Lancet.

[8]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[9]  H. Schumacher,et al.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.

[10]  M. Elisaf,et al.  Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  Ping Zhang,et al.  Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[13]  M. Gertler,et al.  Serum uric acid in relation to age and physique in health and in coronary heart disease. , 1951, Annals of internal medicine.

[14]  K. Tuttle,et al.  Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease. , 2000, Hypertension.

[15]  P. Elliott,et al.  Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database , 2009, BMJ : British Medical Journal.

[16]  H. Schumacher,et al.  Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? , 2005, The American journal of medicine.

[17]  S. Del Prato,et al.  Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin , 2011, Diabetes Care.

[18]  K. Yoon,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial , 2011, Diabetes, obesity & metabolism.

[19]  J. Stockman.  Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials , 2011 .

[20]  David M Eddy,et al.  Archimedes: a trial-validated model of diabetes. , 2003, Diabetes care.

[21]  J. Rosenstock,et al.  Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy , 2012, Diabetes Care.

[22]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.

[23]  Daniel Levy,et al.  Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study , 1999, Annals of Internal Medicine.

[24]  S. Inzucchi,et al.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 , 2013, Diabetes Care.

[25]  B. Rovin,et al.  Uric acid and cardiovascular risk. , 2009, The New England journal of medicine.

[26]  T. Hashimoto,et al.  Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980–1994 , 2004, European Journal of Epidemiology.

[27]  A. Folsom,et al.  Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. , 2000, Annals of epidemiology.

[28]  E. Ford.  Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: Findings from the National Health and Nutrition Examination Survey 1999–2008 * , 2011, Journal of diabetes.

[29]  Alan Brennan,et al.  Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.

[30]  H. Concin,et al.  Secular trends in cardiovascular risk factors: an age‐period cohort analysis of 6 98 954 health examinations in 1 81 350 Austrian men and women , 2007, Journal of internal medicine.

[31]  David M Eddy,et al.  Validation of the archimedes diabetes model. , 2003, Diabetes care.

[32]  S. Daskalopoulou,et al.  The impact of serum uric acid on cardiovascular outcomes in the LIFE study. , 2004, Kidney international.

[33]  David M Eddy,et al.  Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes , 2005, Annals of Internal Medicine.

[34]  K. Pfeiffer,et al.  Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. , 2008, International journal of cardiology.

[35]  Jing Fang,et al.  Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992 , 2000 .